Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?

Abstract

A little more than 6 years ago, the first therapeutic agent targeting cyclic nucleotide phosphodiesterases (PDEs) for the treatment of erectile dysfunction (ED) was introduced into clinical medicine (Boolell et al., 1996). The PDE5 inhibitor sildenafil (Viagra) was the first orally active, effective therapy for the treatment of ED by virtue of its capacity… (More)

1 Figure or Table

Topics

  • Presentations referencing similar topics